The Journal of Hip Surgery 2017; 01(01): 003-006
DOI: 10.1055/s-0036-1597964
Review Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Aging and Cell Therapy for the Treatment of Osteonecrosis of the Femoral Head

Emmanuel Gibon
1   Department of Orthopaedic Surgery, Stanford University, Stanford, California, United States
,
Stuart B. Goodman
1   Department of Orthopaedic Surgery, Stanford University, Stanford, California, United States
2   Department of Bioengineering, Stanford University, Stanford, California, United States
› Author Affiliations
Further Information

Publication History

Publication Date:
31 March 2017 (online)

Abstract

The addition of mesenchymal stem cells (MSCs) to core decompression for the treatment of early-stage osteonecrosis of the femoral head (ONFH) represents a joint preserving operation to potentially avoid hip arthroplasty. The idea to regenerate the proximal femoral bone stock by replenishing the necrotic segment with viable MSCs has shown great promise compared with core decompression alone. However, the fate of the MSCs and the potential effects of aging have posed some important challenges. Aging affects the number of MSCs available for harvesting and injection, as well as their potential for differentiation into the osteogenic lineage, which are two critical parameters for the success of “cell-based therapy” for ONFH. This review endeavors to provide information relevant to the use of MSCs in aging patients for the treatment of ONFH.